The US Food & Drug Administration (FDA) has approved Medtronic’s AdaptiveStim with RestoreSensor neurostimulation system for the management of chronic pain.

The system uses motion sensor technology to provide effective pain relief by automatically adapting stimulation levels to the needs of people with chronic back or leg pain.

It comprises an implantable medical device similar to a pacemaker to hinder pain signals from reaching the brain.

The multicentre, prospective, open-label crossover study randomised 79 study participants to receive either stimulation from the RestoreSensor device for six weeks with the AdaptiveStim technology turned on, followed by six weeks with AdaptiveStim turned off.

In the study, participants reported functional improvements, such as improved comfort during position changes, when the device’s AdaptiveStim technology was turned on.

Medtronic Neuromodulation division pain and drug delivery therapy businesses vice-president and general manager Julie Foster said the company believes that the AdaptiveStim technology will help to treat pain management.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.